Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers

Matthew G. Marin, Jaclyn Van Lieu, Albert Yee, Eileen Bonner, Sherry Glied

Research output: Contribution to journalArticle

Abstract

We performed a cost-effectiveness analysis of a post-exposure chemoprophylaxis program for health care workers who sustained exposures to blood. We analyzed a program of (1) treatment with zidovudine alone versus no treatment and (2) treatment with three-drug therapy versus no treatment. Assuming that 35% of exposures were to HIV-positive sources, the zidovudine regimen prevented 53 HIV seroconversions per 100,000 exposures, at a societal cost of $2.0 million per case of HIV prevented. The cost per quality-adjusted life year saved was $175,222. A three-drug chemoprophylactic therapy program (postulating 100 % effectiveness and 35 % source HIV positivity), prevented 66 seroconversions per 100, 000 exposures, at a cost of $2.1 million per case of HIV prevented and $190,392 per quality-adjusted life year saved. Treating sources known to be HIV-positive and treating severe exposures were the most cost-effective strategies.

Original languageEnglish (US)
Pages (from-to)754-760
Number of pages7
JournalJournal of Occupational and Environmental Medicine
Volume41
Issue number9
DOIs
StatePublished - Sep 1 1999

    Fingerprint

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this